First Use of Control-IQ+ Technology in Newly Indicated Populations
Authors' conclusion
In this first report, Control-IQ+ users experience high time in automation, and those with low and moderate insulin needs exceeded consensus glycemic goals. The majority of users do not use the advanced features routinely, indicating proactive engagement may be useful but is not necessary with Control-IQ+.
Study context
- Population
- Users of Control-IQ+ (t:slim X2 or Tandem Mobi) with ≥14 days and ≥70% CGM availability in Tandem Source, March–June 2025, United States; 51.7% female, median age 45.6 years, 92.8% T1D
- Participants
- 40,320 users
- Exposure
- Control-IQ+ users stratified by total daily insulin (TDI): low vs moderate vs high
- Low TDIn = 451
- Moderate TDIn = 38,259
- High TDIn = 1,610
- Outcome
- TIR
Main finding
As reported in the abstract
- Median time in range (TIR), overall cohort
- 71.4%
Observational data: associations, not effects.
Further findings
Use of advanced features (temp basal, extended bolus)
- Used by the minority of the cohort; Low TDI used them most: temp basal
- 12.2%
- Low TDI: extended bolus
- 26.4%
Safety
- Hypoglycemia rates were low across all groups regardless of TDI
Original publication
First Use of Control-IQ+ Technology in Newly Indicated Populations. Diabetes Technol Ther. Published 10 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →